Company Overview - Henry Schein, Inc. (HSIC) has a market cap of $8.5 billion and is a global healthcare distribution and solutions company headquartered in Melville, New York, serving healthcare professionals in over 30 countries [1] - The company is classified as a "mid-cap" stock, valued between $2 billion and $10 billion, and offers an integrated "one-stop-shop" ecosystem that combines a broad distribution network with software, financial services, and consulting [2] Financial Performance - For FY2025 Q4, Henry Schein reported total net sales of $3.4 billion, a year-over-year increase of 7.7%, and a non-GAAP net income growth of 12.6% to $1.34 [6] - Adjusted EBITDA for the quarter rose 7.8% from the previous year to $291 million, with Global Specialty Products sales increasing by 14.6%, driven by strong dental implant and endodontics sales [6] Stock Performance - HSIC shares have retreated 16.6% from their 52-week high of $89.29 and have declined 2.7% over the past three months, while the S&P 500 Index fell by 4.8% during the same period [3] - Over the past six months, HSIC stock has increased by 7.6%, outperforming the S&P 500's 1.1% increase, but has only climbed 7.3% over the past 52 weeks compared to the S&P 500's 16.1% return [5] - The stock has been trading above its 200-day moving average since November 2025 but has recently slipped below its 50-day moving average [5] Competitive Landscape - Rival Quest Diagnostics Incorporated (DGX) has outperformed HSIC stock, returning 4.6% over the past six months and 17.1% over the past 52 weeks [7] - DGX has a consensus rating of "Moderate Buy" from 16 analysts, with a mean price target of $89.78, representing a 20.6% premium to current levels [7]